Tayo Obafemi-ajayi

Dr. Tayo Obafemi-ajayi

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Biomarker Research
Verified
Journal Article
Open access
PDF file
Daniel B HierDaniel B Hier
Daniel B Hier
TOTayo Obafemi-ajayi
Tayo Obafemi-ajayi
MTMatthew S. Thimgan
Matthew S. Thimgan
GOGayla R. Olbricht
Gayla R. Olbricht
SASima Azizi
Sima Azizi
DWDonald Coolidge Wunsch
Donald Coolidge Wunsch
Background: The use of blood biomarkers after mild traumatic brain injury (mTBI) has been widely studied. We have identified eight unresolved issues related to the use of five commonly investigated blood biomarkers: neurofilament light chain, ubiquitin carboxy-terminal hydrolase-L1, tau, S100B, and glial acidic fibrillary protein. We conducted a focused literature review of unresolved issues in three areas: mode of entry into and exit from the blood, kinetics of blood biomarkers in the blood, and predictive capacity of the blood biomarkers after mTBI. Findings: Although a disruption of the blood brain barrier has been demonstrated in mild and severe traumatic brain injury, biomarkers can enter the blood through pathways that do not require a breach in this barrier. A definitive accounting for the pathways that biomarkers follow from the brain to the blood after mTBI has not been performed. Although preliminary investigations of blood biomarkers kinetics after TBI are available, our current knowledge is incomplete and definitive studies are needed. Optimal sampling times for biomarkers after mTBI have not been established. Kinetic models of blood biomarkers can be informative, but more precise estimates of kinetic parameters are needed. Confounding factors for blood biomarker levels have been identified, but corrections for these factors are not routinely made. Little evidence has emerged to date to suggest that blood biomarker levels correlate with clinical measures of mTBI severity. The significance of elevated biomarker levels thirty or more days following mTBI is uncertain. Blood biomarkers have shown a modest but not definitive ability to distinguish concussed from non-concussed subjects, to detect sub-concussive hits to the head, and to predict recovery from mTBI. Blood biomarkers have performed best at distinguishing CT scan positive from CT scan negative subjects after mTBI.

22 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMostafa Abbas
Mostafa Abbas
JMJohn Matta
John Matta
TLThanh Le
Thanh Le
HBHalima Bensmail
Halima Bensmail
TOTayo Obafemi-ajayi
Tayo Obafemi-ajayi
YEYasser EL-Manzalawy
Yasser EL-Manzalawy
Reliable identification of Inflammatory biomarkers from metagenomics data is a promising direction for developing non-invasive, cost-effective, and rapid clinical tests for early diagnosis of IBD. We present an integrative approach to Network-Based Biomarker Discovery (NBBD) which integrates network analyses methods for prioritizing potential biomarkers and machine learning techniques for assessing the discriminative power of the prioritized biomarkers. Using a large dataset of new-onset pediatric IBD metagenomics biopsy samples, we compare the performance of Random Forest (RF) classifiers trained on features selected using a representative set of traditional feature selection methods against NBBD framework, configured using five different tools for inferring networks from metagenomics data, and nine different methods for prioritizing biomarkers as well as a hybrid approach combining best traditional and NBBD based feature selection. We also examine how the performance of the predictive models for IBD diagnosis varies as a function of the size of the data used for biomarker identification. Our results show that (i) NBBD is competitive with some of the state-of-the-art feature selection methods including Random Forest Feature Importance (RFFI) scores; and (ii) NBBD is especially effective in reliably identifying IBD biomarkers when the number of data samples available for biomarker discovery is small.

28 September 2020 in IEEE Access
Verified
Journal Article
Open access
DYDacosta Yeboah
Dacosta Yeboah
LSLouis Steinmeister
Louis Steinmeister
Daniel B HierDaniel B Hier
Daniel B Hier
BHBassam Hadi
Bassam Hadi
DWDonald Coolidge Wunsch
Donald Coolidge Wunsch
TOTayo Obafemi-ajayi
Tayo Obafemi-ajayi
We present a framework for an explainable and statistically validated ensemble clustering model applied to Traumatic Brain Injury (TBI). The objective of our analysis is to identify patient injury severity subgroups and key phenotypes that delineate these subgroups using varied clinical and computed tomography data. Explainable and statistically-validated models are essential because a data-driven identification of subgroups is an inherently multidisciplinary undertaking. In our case, this procedure yielded six distinct patient subgroups with respect to mechanism of injury, severity of presentation, anatomy, psychometric, and functional outcome. This framework for ensemble cluster analysis fully integrates statistical methods at several stages of analysis to enhance the quality and the explainability of results. This methodology is applicable to other clinical data sets that exhibit significant heterogeneity as well as other diverse data science applications in biomedicine and elsewhere.

29 August 2018 in Applied Network Science
Verified
Journal Article
Open access
PDF file
JMJohn Matta
John Matta
JZJunya Zhao
Junya Zhao
GEGunes Ercal
Gunes Ercal
TOTayo Obafemi-ajayi
Tayo Obafemi-ajayi
With the growing ubiquity of data in network form, clustering in the context of a network, represented as a graph, has become increasingly important. Clustering is a very useful data exploratory machine learning tool that allows us to make better sense of heterogeneous data by grouping data with similar attributes based on some criteria. This paper investigates the application of a novel graph theoretic clustering method, Node-Based Resilience clustering (NBR-Clust), to address the heterogeneity of Autism Spectrum Disorder (ASD) and identify meaningful subgroups. The hypothesis is that analysis of these subgroups would reveal relevant biomarkers that would provide a better understanding of ASD phenotypic heterogeneity useful for further ASD studies. We address appropriate graph constructions suited for representing the ASD phenotype data. The sample population is drawn from a very large rigorous dataset: Simons Simplex Collection (SSC). Analysis of the results performed using graph quality measures, internal cluster validation measures, and clinical analysis outcome demonstrate the potential usefulness of resilience measure clustering for biomedical datasets. We also conduct feature extraction analysis to characterize relevant biomarkers that delineate the resulting subgroups. The optimal results obtained favored predominantly a 5-cluster configuration.

24 June 2021 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
LBLien A. Bui
Lien A. Bui
DYDacosta Yeboah
Dacosta Yeboah
LSLouis Steinmeister
Louis Steinmeister
SASima Azizi
Sima Azizi
Daniel B HierDaniel B Hier
Daniel B Hier
TOTayo Obafemi-ajayi
Tayo Obafemi-ajayi
Concussions, also known as mild traumatic brain injury (mTBI), are a growing health challenge. Approximately four million concussions are diagnosed annually in the United States. Concussion is a heterogeneous disorder in causation, symptoms, and outcome making precision medicine approaches to this disorder important. Persistent disabling symptoms sometimes delay recovery in a difficult to predict subset of mTBI patients. Despite abundant data, clinicians need better tools to assess and predict recovery. Data-driven decision support holds promise for accurate clinical prediction tools for mTBI due to its ability to identify hidden correlations in complex datasets. We apply a Locality-Sensitive Hashing model enhanced by varied statistical methods to cluster blood biomarker level trajectories acquired over multiple time points. Additional features derived from demographics, injury context, neurocognitive assessment, and postural stability assessment are extracted using an autoencoder to augment the model. The data, obtained from FITBIR, consisted of 301 concussed subjects (athletes and cadets). Clustering identified 11 different biomarker trajectories. Two of the trajectories (rising GFAP and rising NF-L) were associated with a greater risk of loss of consciousness or post-traumatic amnesia at onset. The ability to cluster blood biomarker trajectories enhances the possibilities for precision medicine approaches to mTBI.

1 August 2015
Verified
Conference Paper
Closed access
TOTayo Obafemi-ajayi
Tayo Obafemi-ajayi
DLDao Lam
Dao Lam
TTT. Nicole Takahashi
T. Nicole Takahashi
SKStephen M. Kanne
Stephen M. Kanne
DWDonald Coolidge Wunsch
Donald Coolidge Wunsch
Autism spectrum disorder (ASD) is characterized by notable phenotypic heterogeneity, which is often viewed as an obstacle to the study of its etiology, diagnosis, treatment, and prognosis. Heterogeneity in ASD is multidimensional and complex including variability in phenotype as well as clinical, physiologic, and pathologic parameters. We apply a hierarchical clustering model suited to dealing with datasets of mixed data types to stratify children with ASD into more homogeneous subgroups in line with the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 model. The results of this cluster analysis will provide a better understanding the complex issue of ASD phenotypic heterogeneity and identify subgroups useful for further ASD genetic studies. Our goal is to provide insight into viable phenotypic and genotypic markers that would guide further cluster analysis of ASD genetic data. We suggest that analyzing the clusters in a hierarchical structure is a well-suited and meaningful model to unravel the complex heterogeneity of this disorder.